The outcomes of the first clinical trial demonstrate the safety and efficacy of the measles-rubella (MR) vaccination to adults and infants as young as 9 months.
/PRNewswire/ The "Molecular Cytogenetics: Global Strategic Business Report" report has been added to ResearchAndMarkets.com s offering. The global market.